title: Monoclonal antibody-based therapy for renal cell carcinoma.
abstract: Monoclonal antibody G250 treatment may have a role in the management of metastatic RCC; however, particular subgroups who are more prone to benefit from this treatment must be delineated. High-risk patients may benefit from adjuvant treatment with this nontoxic treatment modality. Large cohort studies are needed to investigate this possibility.
authors.affiliation: Nijmegen Center for Molecular Life Sciences, 190 Experimental Urology, University Medical Center Nijmegen, Geert Grooteplein Zuid 28, 6525 Nijmegen, The Netherlands. e.oosterwijk@uro.umcn.nl
authors.forename: Egbert
authors.initials: E
authors.lastname: Oosterwijk
authors.forename: Chaitanya R
authors.initials: CR
authors.lastname: Divgi
authors.forename: Adrienne
authors.initials: A
authors.lastname: Brouwers
authors.forename: Otto C
authors.initials: OC
authors.lastname: Boerman
authors.forename: Steven M
authors.initials: SM
authors.lastname: Larson
authors.forename: Peter
authors.initials: P
authors.lastname: Mulders
authors.forename: Lloyd J
authors.initials: LJ
authors.lastname: Old
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; C400566:antigen G250